Zura Bio (NASDAQ:ZURA) Trading Up 11.8% – Still a Buy?

Zura Bio Limited (NASDAQ:ZURA)’s stock price rose 11.8% during trading on Monday . The stock traded as high as $5.95 and last traded at $6.5430. Approximately 257,271 shares changed hands during trading, a decline of 69% from the average session volume of 830,721 shares. The stock had previously closed at $5.85.

Wall Street Analysts Forecast Growth

ZURA has been the subject of several research analyst reports. Guggenheim upped their price objective on shares of Zura Bio from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a research report on Monday, July 6th. William Blair started coverage on Zura Bio in a report on Wednesday, July 8th. They issued an “outperform” rating for the company. Wall Street Zen raised Zura Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Finally, Wedbush raised their price target on Zura Bio from $15.00 to $22.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

Zura Bio Stock Up 0.3%

The stock has a market capitalization of $605.65 million, a PE ratio of -5.59 and a beta of -0.02. The firm’s fifty day moving average is $5.32 and its 200-day moving average is $5.39.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings data on Tuesday, June 30th. The company reported ($0.21) earnings per share for the quarter. On average, analysts expect that Zura Bio Limited will post -0.81 EPS for the current year.

Institutional Trading of Zura Bio

A number of institutional investors have recently modified their holdings of ZURA. California State Teachers Retirement System acquired a new stake in Zura Bio in the second quarter valued at $28,000. Allworth Financial LP purchased a new position in shares of Zura Bio in the 4th quarter valued at about $30,000. Scientech Research LLC purchased a new position in shares of Zura Bio in the 3rd quarter valued at about $45,000. Dimensional Fund Advisors LP acquired a new stake in shares of Zura Bio in the fourth quarter valued at about $123,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Zura Bio in the third quarter valued at about $109,000. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.